Agila receives USFDA approval for Zoledronic Acid injection

According to IMS data, the US market for Zoledronic Acid 5ML is approximately $520 million

Pradeesh Chandran Bangalore
Last Updated : Mar 06 2013 | 11:13 AM IST
Agila Specialties Pvt Ltd, a wholly owned subsidiary of Strides Arcolab Limited, on Wednesday said it has received Abbreviated New Drug Application (ANDA) approval for Zoledronic Acid Injection 4mg/5 mg, packaged in single dose vials.

Zoledronic Acid is used to treat high blood calcium levels (hypercalcemia) that may occur with cancer. It is also used with cancer chemotherapy to treat bone problems that may occur with multiple myeloma and other types of cancer such as breast, lung that have spread to bones.  

According to IMS data, the US market for Zoledronic Acid 5ML is approximately $520 million. The company expects to launch the product shortly.   

In morning trade on BSE, the shares of Strides Arcolab were trading at Rs 900.05, up 2.53%.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 06 2013 | 11:12 AM IST

Next Story